We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04594031
Recruitment Status : Withdrawn (Preference given to gene therapy approaches by the SCD research community and patients' associations)
First Posted : October 20, 2020
Last Update Posted : July 5, 2022
California Institute for Regenerative Medicine (CIRM)
Information provided by (Responsible Party):
ExCellThera inc.

Brief Summary:

The application of experimental hematopoietic cell transplantation (HCT) therapy in sickle-cell disease (SCD) must strike a balance between the underlying disease severity and the possibility of a direct benefit of the treatment, particularly in pediatric populations. Clinical studies in adults with SCD have focused on interventions that prolong survival and improve the quality of life. Unlike children, adults with SCD are much more likely to have a debilitating complication. As a result, the risk/benefit ratio of HCT is very favorable in adults, particularly if an approach to HCT that defines an acceptable level of toxicity can be established.

Whereas hematopoietic stem cell transplantation (HSCT) remains the only curative treatment currently available for patients with SCD, the morbidity, the frequent irreversible damage in target organs and the mortality reported in the natural course of patients with severe SCD are strong incentives to perform HSCTs in younger age groups. For those who lack a matched related donor, CB transplant is an appealing option, but despite been less problematic, CB accessibility related to cell dose of appropriately matched cord blood unit (CBU) remains a significant issue. Through a 7-day culture process of a CBU's hematopoietic stem cell HSCs with the UM171 compound, the total cell dose is increased mitigating this limitation.

UM171-CB expansion (ECT-001-CB) allows a greater CB accessibility, the selection of better matched cords that might translate into favourable clinical outcomes as reported in previous trials, including a lower risk of graft-versus-host disease. After CB selection and ex-vivo expansion, ECT-001-CB transplant will follow a myeloablative reduced-toxicity conditioning regimen consisting of rATG, busulfan and fludarabine with doses of all agents optimized to the individual using model-based dosing and will be followed by standard supportive care and GVHD prophylaxis consisting of tacrolimus and MMF.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Umbilical Cord Blood Hematopoietic Cell Proliferation Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Multicenter Study of Hematopoietic Stem Cell Transplant of ECT-001-Expanded Cord Blood With a Reduced Toxicity Conditioning Regimen in Patients With Severe Sickle Cell Disease
Actual Study Start Date : July 13, 2021
Estimated Primary Completion Date : September 1, 2023
Estimated Study Completion Date : February 2, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ECT-001-CB
  • An Umbilical Cord Blood for transplant will undergo CD34+ selection and expansion. The CD34- fraction is infused on Day +1 post-transplant.
  • Patients will receive standard supportive care and GVHD prophylaxis
Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Single ECT-001-CB transplant (CD34+: 2 to 5.75x10E5/kg, CD3+ >1x10E6/kg)

Primary Outcome Measures :
  1. Evaluate feasibility of finding a suitable ECT-001-CB graft for transplantation in the context of SCD. [ Time Frame: Up to 24-months ]
    Calculate the proportion of recruited SCD patients for whom a suitable CBU (i.e., ≥ 6/8 human leukocyte antigen (HLA) with an appropriate cell dose) is identified.

  2. Evaluate feasibility of a successfully performing ECT-001-CB transplantation in the context of SCD. [ Time Frame: During accrual (up to 24-months) ]
    Calculate the percentage of selected grafts that will be successfully expanded and transplanted with absence of technical hurdles

  3. Evaluate the Safety of ECT-001-CB by evaluating tri-lineage hematopoietic reconstitution [ Time Frame: Up to 12-Months ]
    Measure the time required to achieve neutrophil and platelet engraftment

  4. Evaluate the Safety of ECT-001-CB by calculating incidence of acute and chronic GvHD [ Time Frame: Up to 12-Months ]
    Calculate incidence of Acute GVHD and Chronic GVHD as per NIH criteria

  5. Evaluate the Safety of ECT-001-CB by evaluating adverse events [ Time Frame: Up to 12-Months ]
    Calculate the Incidence of Adverse Events from the beginning of the conditioning regimen up to 12 months after ECT-001-CB transplant

  6. Evaluate the Safety of ECT-001-CB by evaluating incidence of transplant related mortality (TRM) [ Time Frame: Up to 12-Months ]
    Calculate incidence of any mortality related to the investigational product until the end of evaluation period.

  7. Evaluate the Safety of ECT-001-CB by incidence of graft failure [ Time Frame: Up to 100 days ]
    Calculate the incidence of primary and late graft failure

Secondary Outcome Measures :
  1. Determine the pharmacologic effect of ECT-001-CB by evaluating donor chimerism [ Time Frame: Up to 12-Months post treatment ]
    The percentage of hematopoietic chimerism, based on DNA polymorphisms, will be measured and compared to baseline.

  2. Determine the pharmacologic effect of ECT-001-CB by measuring sickle hemoglobin (HbS) in peripheral blood. [ Time Frame: Up to 12-Months post treatment ]
    The concentration of the Sickle Hemoglobin (HbS) will be compared to baseline.

  3. Evaluate impact of ECT-001-CB on SCD-related events during the study period. [ Time Frame: Up to 12-Months post treatment ]
    The incidence of SCD-related adverse events will be compared to internal controls

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be ≥ 5-30 years of age.
  2. Have a diagnosis of SCD, with either βS/βS, βS/β0, βS/β+ or βS/βC genotype and followed at a center of excellence for SCD with at least 2 years of detailed past medical records available.
  3. Have severe disease i.e. have experienced one or more of the following SCD related events, in spite of appropriate supportive care measures (e.g. pain management, penicillin prophylaxis):

    1. Recurrent severe vaso-occlusive crisis (VOC) (≥2 episodes/year in the prior 2 years): an episode of pain lasting >2 hours severe enough to require care at a medical facility. Note that priapism that lasts >2 hours and requires care at a medical facility is also considered a VOC. To meet this criterion, subjects must have either experienced hydroxyurea failure at any point in the past (defined as >1 VOC or ≥1 acute chest syndrome (ACS) after taking hydroxyurea for ≥3 months) or must have intolerance to hydroxyurea (defined as inability to be maintained on an adequate dose of hydroxyurea due to marrow suppression or severe drug-induced toxicity [e.g. gastrointestinal distress, fatigue]).
    2. ACS (≥2 total episodes in the prior 2 years, with at least one episode in the past year), defined as an acute event with pneumonia-like symptoms, hypoxemia and the presence of a new pulmonary infiltrate. To meet this criterion, subjects must have either experienced hydroxyurea failure or have intolerance to hydroxyurea, as defined above.
    3. History of an overt stroke, defined as a sudden onset neurologic deficit lasting more than 24 hours that is accompanied by cerebral MRI changes.
    4. patients on chronic transfusions are eligible, provided medical records documenting any of the above severity criteria are available prior to starting the transfusion program.
  4. Availability of 1 CB unit ≥ 6/8 HLA match (when A, B, C and DRB1 are performed at the allelic level resolution) with of at least CD34+ cell count 1.5 x 105/kg and total nucleated cells (TNC) 1.5 x 107/kg (pre-freeze)
  5. Have adequate organ function to undergo a myeloablative (reduced toxicity conditioning) HSCT.
  6. Have a Lansky/Karnofsky performance status of ≥ 80.
  7. An appropriate and willing HLA-matched sibling donor is not available.

Exclusion Criteria:

  1. Prior HSCT or gene-therapy.
  2. Positive for presence of HIV-1 or HIV-2, hepatitis B virus (HBV), or hepatitis C virus (HCV). (Note that patients who have been vaccinated against hepatitis B [hepatitis B surface antibody (HBsAb)-positive] or patients with positive hepatitis B core and/or hepatitis B-e antibodies are also eligible provided viral load is negative by quantitative polymerase chain reaction (qPCR). Patients who are positive for anti-hepatitis C antibody are eligible as long as they have a negative HCV viral load by qPCR). Positive serology for human T-lymphotropic virus-1 (HTLV-1), syphilis (rapid plasma reagin (RPR)), toxoplasmosis.
  3. Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by PI.
  4. A white blood cell count <2 × 10e9/L, and/or platelet count <50 × 10e9/L.
  5. Any prior or current malignancy or myeloproliferative or a significant coagulation or immunodeficiency disorder.
  6. Advanced liver disease, defined as:

    1. Persistent aspartate transaminase, alanine transaminase, or direct bilirubin value >5 times the upper limit of normal (ULN); or
    2. Cirrhosis or bridging fibrosis; or
    3. Baseline prothrombin time or partial thromboplastin time > 1.5 x ULN; or
    4. in chronically transfused patients a liver iron concentration (LIC) of ≥ 15 mg/g on T2* Magnetic Resonance Imaging [MRI] of liver.
  7. Left ventricular ejection fraction (LVEF) <45% and for patients on chronic transfusions a cardiac T2* < 10 ms by MRI.
  8. Baseline estimated glomerular filtration rate < 60 mL/min/1.73 m2.
  9. Baseline oxygen saturation < 85% without supplemental oxygen (excluding periods of SCD crisis or infection).
  10. Diffusion capacity of carbon monoxide (DLCO) <50% of predicted (corrected for hemoglobin and/or alveolar volume).
  11. Any contraindication to general anaesthesia.
  12. Participation in another clinical study with an investigational drug within 30 days of Screening.
  13. Diagnosis of a significant psychiatric disorder as deemed as the PI that could seriously impede the subject's ability to participate in the study.
  14. Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile patients. Females of child bearing potential are required to use effective contraception from enrollment through at least 6 months after drug product infusion. Male patients are required to use effective contraception from enrollment through at least 6 months after drug product infusion.
  15. An assessment by the PI that the subject would not comply with the study procedures outlined in the protocol.
  16. Any abnormal condition or laboratory result that is considered by the PI capable of altering patient condition or study outcome.

Note: should a patient be out of range for any numerical exclusion criteria, the PI is allowed to repeat the dosage once during the screening period to definitely determine eligibility

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04594031

Layout table for location information
United States, California
Stanford University School of Medicine
Palo Alto, California, United States, 94304
University of California San Francisco
San Francisco, California, United States, 94158
Sponsors and Collaborators
ExCellThera inc.
California Institute for Regenerative Medicine (CIRM)
Layout table for investigator information
Study Director: Medical Monitor ExCellThera inc.
Layout table for additonal information
Responsible Party: ExCellThera inc.
ClinicalTrials.gov Identifier: NCT04594031    
Other Study ID Numbers: ECT-001.CB.005
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: July 5, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn